Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 4:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1753–1776 of 27,816 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo and sham treatment Clear all
Recruiting Phase 2 Interventional

Aquamin® for Prevention of Ulcerative Colitis J-Pouch-associate Intestinal Inflammation

NCT07501078
View directory record Official record
Conditions
Ulcerative Colitis, Ileal Pouch
Interventions
Aquamin, Placebo
Drug
Lead sponsor
Muhammad N Aslam, MD
Other
Eligibility
18 Years to 80 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 29, 2026, 4:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety and Tolerability of E2730 After Multiple Dose and the Food Effect After Single Dose in Healthy Participants

NCT04676685
View directory record Official record
Conditions
Healthy Volunteers
Interventions
E2730, E2730-matched placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Aug 26, 2021 · Synced Oct 29, 2026, 4:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity of Peru-15-pCTB in Healthy Adult Subjects

NCT00654108
View directory record Official record
Conditions
Gastroenteritis Escherichia Coli
Interventions
Ciprofloxacin, Peru-15-pCTB, Sodium bicarbonate/Ascorbic Acid/Aspartame Buffer
Drug · Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 29, 2021 · Synced Oct 29, 2026, 4:24 PM EDT
Completed Phase 3 Interventional Results available

Mepolizumab Steroid-Sparing Study in Subjects With Severe Refractory Asthma

NCT01691508
View directory record Official record
Conditions
Asthma
Interventions
Mepolizumab, Placebo, OCS (prednisone/prednisolone)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
8
States / cities
Long Beach, California • Denver, Colorado • New Haven, Connecticut + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2017 · Synced Oct 29, 2026, 4:24 PM EDT
Recruiting Phase 2Phase 3 Interventional

Study of Choline Chloride for Injection in Adolescent and Adult Patients With Intestinal Failure Receiving Long Term Parenteral Support

NCT06910943
View directory record Official record
Conditions
Choline Deficiency, Liver Injury
Interventions
Choline Chloride for Injection, Placebo
Drug
Lead sponsor
Protara Therapeutics
Industry
Eligibility
12 Years and older
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
8
States / cities
Aurora, Colorado • Miami Lakes, Florida • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 29, 2026, 4:24 PM EDT
Active, not recruiting Phase 2 Interventional

A Study of RSLV-132 in Females With Sjögren's Disease

NCT06440525
View directory record Official record
Conditions
Primary Sjögren Syndrome
Interventions
RSLV-132, Placebo
Drug
Lead sponsor
Resolve Therapeutics
Industry
Eligibility
18 Years to 75 Years · Female only
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
24
States / cities
Chula Vista, California • Tustin, California • Boca Raton, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 29, 2026, 4:24 PM EDT
Completed Not applicable Interventional

Theta Burst Stimulation for Refractory Depression in Autism Spectrum Disorder

NCT06670040
View directory record Official record
Conditions
ASD, Autism Spectrum Disorder, Autism, Depression - Major Depressive Disorder, MDD
Interventions
Transcranial Magnetic Stimulation, Transcranial Magnetic Stimulation Sham
Procedure
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
13 Years to 26 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 29, 2026, 4:24 PM EDT
Terminated Phase 3 Interventional

A Study of the Effects of AB-205 in Patients With Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation

NCT05181540
View directory record Official record
Conditions
Hodgkin Lymphoma, Non Hodgkin Lymphoma
Interventions
AB-205, Placebo
Biological · Other
Lead sponsor
Angiocrine Bioscience
Industry
Eligibility
40 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
28
States / cities
Gilbert, Arizona • Duarte, California • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Oct 29, 2026, 4:24 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A 3-part Study of SYX-5219 in Healthy Volunteers and Participants With Atopic Dermatitis

NCT07558668
View directory record Official record
Conditions
Moderate to Severe Atopic Dermatitis
Interventions
SYX-5219 Oral Capsule
Drug
Lead sponsor
Sitryx Therapeutics Ltd
Industry
Eligibility
18 Years to 65 Years
Enrollment
149 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
6
States / cities
Arkansas City, Arkansas • Fremont, California • Plainfield, Indiana + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 29, 2026, 4:24 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety, Tolerability, PK and PD of Posiphen® in Subjects With Early Alzheimer's Disease

NCT02925650
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Posiphen, Placebo
Drug
Lead sponsor
Annovis Bio Inc.
Industry
Eligibility
55 Years to 89 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
6
States / cities
La Jolla, California • Indianapolis, Indiana • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated May 9, 2023 · Synced Oct 29, 2026, 4:24 PM EDT
Terminated Phase 3 Interventional Results available

Safety and Efficacy of Selonsertib in Adults With Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis

NCT03053050
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis
Interventions
SEL, Placebo to match SEL 6 mg, Placebo to match SEL 18 mg
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 70 Years
Enrollment
808 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
124
States / cities
Chandler, Arizona • Phoenix, Arizona • Tucson, Arizona + 95 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2020 · Synced Oct 29, 2026, 4:24 PM EDT
Completed Phase 2 Interventional

Study Evaluating the Safety and Efficacy of MN-221 as an Adjunct to Standard Therapy in Subjects Experiencing an Acute Exacerbation of Asthma

NCT00838591
View directory record Official record
Conditions
Asthma
Interventions
MN-221, Placebo
Drug
Lead sponsor
MediciNova
Industry
Eligibility
18 Years to 65 Years
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
15
States / cities
Loma Linda, California • San Diego, California • Sylmar, California + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2013 · Synced Oct 29, 2026, 4:24 PM EDT
Completed Not applicable Interventional Results available

Heat Therapy to Reduce Pain and Improve Walking Tolerance

NCT03435835
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
Control/Sham Treatment, Heat Therapy (HT)
Device
Lead sponsor
Indiana University
Other
Eligibility
Not listed
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 30, 2022 · Synced Oct 29, 2026, 4:24 PM EDT
Terminated Phase 2 Interventional Results available

Effect of Vandetanib on Cellular Markers in Invasive Breast Cancer

NCT01934335
View directory record Official record
Conditions
Invasive Breast Cancer
Interventions
Vandetanib, Placebo
Drug · Other
Lead sponsor
Ronald Weigel
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 29, 2026, 4:24 PM EDT
Completed Phase 3 Interventional Results available

Temporary Gastric Electrical Stimulation for Drug Refractory Gastroparesis

NCT00432835
View directory record Official record
Conditions
Gastroparesis
Interventions
Gastric Electrical Stimulator, Enterra, Medtronics, Inc.
Device
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Dec 3, 2012 · Synced Oct 29, 2026, 4:24 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

A Comparison of Tolterodine and Placebo Treatments on Nocturnal Frequency and Sleep Quality in Women After Menopause.

NCT00323635
View directory record Official record
Conditions
Urinary Incontinence
Interventions
tolterodine
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
45 Years to 65 Years · Female only
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2011
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 29, 2018 · Synced Oct 29, 2026, 4:24 PM EDT
Terminated Phase 3 Interventional Results available

A Study of Aticaprant Plus an Antidepressant to Prevent Return of Depression Symptoms in Participants With Major Depressive Disorder Who Experience a Loss of Interest and Pleasure

NCT06635135
View directory record Official record
Conditions
Depressive Disorder, Major, Anhedonia
Interventions
Aticaprant, Placebo
Drug · Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
31
States / cities
Little Rock, Arkansas • Encino, California • Newport Beach, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 29, 2026, 4:24 PM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety, and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations

NCT00368108
View directory record Official record
Conditions
Parkinson's Disease
Interventions
2 mg perampanel, 4 mg perampanel, placebo comparator
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
30 Years and older
Enrollment
752 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
99
States / cities
Birmingham, Alabama • Huntsville, Alabama • Peoria, Arizona + 82 more
Source: ClinicalTrials.gov public record
Updated May 20, 2013 · Synced Oct 29, 2026, 4:24 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Placebo-controlled Trial of 5-hydroxytryptophan and Creatine for SSRI or SNRI Augmentation in Treatment Resistant Depression in Females

NCT02922725
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
5-hydroxytryptophan and Creatine, Placebo control
Drug · Other
Lead sponsor
Brent Michael Kious, MD, PhD
Other
Eligibility
25 Years to 40 Years · Female only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 31, 2022 · Synced Oct 29, 2026, 4:24 PM EDT
Not yet recruiting Phase 2 Interventional

Rimegepant For Endometriosis Pain

NCT07795125
View directory record Official record
Conditions
Endometriosis, Endometriosis-related Pain
Interventions
Rimegepant 75 MG, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 29, 2026, 4:24 PM EDT
Completed Phase 2Phase 3 Interventional

Study of Pexacerfont (BMS-562086) in the Treatment of Outpatients With Generalized Anxiety Disorder

NCT00481325
View directory record Official record
Conditions
Generalized Anxiety Disorder
Interventions
pexacerfont, escitalopram, placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
51
States / cities
Mesa, Arizona • Burbank, California • Costa Mesa, California + 42 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2015 · Synced Oct 29, 2026, 4:24 PM EDT
Completed Phase 3 Interventional Results available

AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

NCT02296125
View directory record Official record
Conditions
Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer
Interventions
AZD9291 80 mg/40 mg + placebo, Placebo Erlotinib 150/100mg, Placebo Gefitinib 250 mg, Erlotinib 150/100 mg, Gefitinib 250 mg, Placebo AZD9291 80 mg/ 40 mg
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 100 Years
Enrollment
674 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
14
States / cities
Anaheim, California • Santa Rosa, California • West Hills, California + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 29, 2026, 4:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Clinical and Immune Response to Two Dengue Virus Vaccines in Healthy Adults

NCT02392325
View directory record Official record
Conditions
Dengue
Interventions
rDEN1Δ30, Placebo, rDEN2Δ30-7169
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 8, 2018 · Synced Oct 29, 2026, 4:24 PM EDT
Completed Phase 2 Interventional Results available

A Study Evaluating the Safety, Tolerability, and Pharmacodynamic Effects of GLY-200 in Type 2 Diabetic Patients

NCT05478525
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
GLY-200, Placebo
Drug
Lead sponsor
Glyscend, Inc.
Industry
Eligibility
30 Years to 70 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Feb 10, 2025 · Synced Oct 29, 2026, 4:24 PM EDT